ENGOT-Ov65/KEYNOTE-B96: Phase III, Randomized, Double-Blind Study Of Pembrolizumab Vs Placebo Plus Paclitaxel With Optional Bevacizumab For Platinum-Resistant Recurrent Ovarian Cancer

No Thumbnail Available

Files

96.pdf (125.2 KB)

Date

2022

Authors

Journal Title

Journal ISSN

Volume Title

Publisher

Abstract

Description

Keywords

Citation

URI

https://reader.elsevier.com/reader/sd/pii/S0923753422007475?token=FF8368913AFE07B7B27DE123C04BD2F1633BBD9FEEFA29DFEB4FCD09F08399C552B8F5EFD2205FC9C9DC7CACA5507110&originRegion=eu-west-1&originCreation=20221219072044
 http://hdl.handle.net/11727/8330

Collections

Tıp Fakültesi / Faculty of Medicine
Wos Açık Erişimli Yayınlar
Wos İndeksli Yayınlar Koleksiyonu

Endorsement

Review

Supplemented By

Referenced By